CLASS 1 CORTICOSTEROID1

Ultravate® Lotion

(halobetasol propionate) 0.05%
  • 60 mL bottle
  • 120 mL (2 bottles of 60 mL)

ULTRAVATE (halobetasol propionate) 0.05% Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

Class 1 potency in a lotion formulation1

  • Ideal for the treatment of large body surface areas, elbows, and knees
  • ULTRAVATE Lotion contains rich emollients to increase and maintain skin moisturization2
  • Class 1 potency demonstrated in 2 clinical studies of patients with moderate-to-severe plaque psoriasis1,3
    — 45% of patients were clear or almost clear in both studies3

See the results

Baseline

At Day 14

Female with plaque psoriasis on her lower leg, treated with ULTRAVATE Lotion twice daily for 14 days.*

*Individual patient results. Actual results may vary.

INDICATIONS AND USAGE

• 
ULTRAVATE (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

IMPORTANT SAFETY INFORMATION

• 
Effects on Endocrine System: Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic efforts of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. System absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical steroids.
• 
Local Adverse Reactions: Local adverse reactions with topical steroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection and miliaria. These may be more likely to occur with occlusive use, prolonged use or more potent corticosteroids, including ULTRAVATE.
• 
Concomitant Skin Infections: Use an appropriate antimicrobial agent if a skin infection is present or develops.
• 
Allergic Contact Dermatitis: Discontinue ULTRAVATE Lotion if allergic contact dermatitis is established.
• 
In clinical trials the most common adverse reactions (≥1%) were telangiectasia, application site atrophy, and headache.
Please click here to see the Full Prescribing Information.

References: 1. National Psoriasis Foundation. Topical steroids potency chart. https://www.psoriasis.org/about-psoriasis/treatments/topicals/steroids/potency-chart. Updated 2016. Accessed February 4, 2019. 2. Grove G, Zerweck C, Houser T, et al. Occlusivity and moisturization potential of a new lotion formulation of halobetasol propionate, 0.05%. Poster presented at: 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC. 3. ULTRAVATE® Lotion [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017.